Objective: To investigate the relationship between the polymorphism of miR-155 and its target gene MyD88 and clinicopathological features of diffuse large B-cell lymphoma (DLBCL).
Methods: 135 cases of DLBCL patients in our hospital from March 2015 to August 2017 were selected, and 90 cases of reactive hyperplasia of lymph nodes were selected as the control group. The relative expression of miR-155 and MyD88 gene polymorphism were detected in the two groups, and the relationship between miR-155 and MyD88 gene polymorphism and clinicopathological characteristics of DLBCL was analyzed.
Results: The relative expression of miR-155 in DLBCL patients was significantly higher than that in the control group (P<0.05). The mutation rate of MyD88 L265P in DLBCL group was significantly higher than that in control group (P<0.05). The relative expression of miR-155 in patients with MyD88 L265P mutation was significantly higher than that in patients with wild-type DLBCL (P<0.05). The relative expression of miR-155 and the polymorphism of MyD88 L265P were associated with lesion location, stage, BCL-2 protein expression and MyD88 protein expression in DLBCL patients (t=7.461、8.804、6.487、10.812； χ2=10.681、8.599、7.251、23.008；P<0.05). The survival of DLBCL patients with low miR-155 expression was significantly better than that with high miR-155 expression (P<0.05). The survival of wild-type DLBCL patients with MyD88 L265P locus was significantly better than that of mutant DLBCL patients (P<0.05). There was a significant positive correlation between the relative expression of miR-155 and the expression of MyD88 protein (r=0.428, P=0.000).
Conclusion: The abnormal expression of miR-155 and the mutation rate of MyD88 gene in DLBCL patients are increased, and the expression of miR-155 and the mutation of MyD88 gene affect the disease progression and prognosis of patients, which may be potential biological indicators for the diagnosis, treatment and prognosis of DLBCL.
题目: miR-155及其靶基因MyD88基因多态性与弥漫大B细胞淋巴瘤临床病理特征的关系.
目的: 探讨分析miR-155及其靶基因MyD88基因多态性与弥漫大B细胞淋巴瘤（DLBCL）临床病理特征的关系.
方法: 选择2015年3月-2017年8月本院收治的DLBCL患者135例，另外选择淋巴结反应性增生标本90例作为对照组。检测2组受试者miR-155相对表达量及MyD88基因多态性，并分析miR-155及MyD88基因多态性与DLBCL临床病理特征的关系.
结果: DLBCL患者miR-155相对表达量显著高于对照组（P<0.05）。DLBCL组患者MyD88 L265P位点突变率显著高于对照组（P<0.05）。MyD88 L265P位点突变型DLBCL患者miR-155相对表达量显著高于野生型患者（P<0.05）。DLBCL患者miR-155相对表达量、MyD88 L265P位点基因多态性与患者病变部位、分期、BCL-2蛋白表达以及MyD88蛋白表达有关（t=7.461、8.804、6.487、10.812；χ2=10.681、8.599、7.251、23.008；P<0.05）。miR-155低表达DLBCL患者生存情况显著优于miR-155高表达患者（P<0.05）。MyD88 L265P位点野生型DLBCL患者生存情况显著优于突变型患者（P<0.05）。miR-155相对表达量与MyD88蛋白表达呈显著正相关（r=0.428，P=0.000）.
结论: DLBCL患者表现为miR-155表达异常升高以及MyD88基因突变率升高，且miR-155表达与MyD88基因突变影响患者疾病进展及预后，可能成为DLBCL诊断、治疗及预后判断的潜在生物学指标.